Ali Bazarbachi, MD, PhD is a Professor of Medicine (Hematology and Oncology), Professor of Anatomy, Cell Biology and Physiological Sciences, Associate Dean for basic research, and Director of the bone marrow transplantation program at the American University of Beirut-Medical Center. He received his MD and PhD degrees, residency and fellowship training at the University of Paris VII in France. Dr. Ali Bazarbachi’s research focuses on developing oncogene-targeted therapies for human leukemia and lymphoma as well as post-transplant pharmalogical interventions. He has co-authored more than 225 articles in leading scientific journals including The New England Journal of Medicine, Science, Journal of Experimental Medicine, The Lancet Oncology, Journal of Clinical Oncology, Blood, Leukemia, Cell Death and Differentiation, Oncogene, and Cancer Research, and serves as a reviewer for many of these journals. He is the Chairman of the EMBMT Leukemia Working Party, Chairman of the NCCN Lymphoma Group for Middle East and North Africa, past President of the Lebanese Society of Hematology, and Associate Editor of Bone Marrow Transplantation.
Didier Blaise leads the program in Blood and Marrow Transplantation and Cellular immunotherapy since 1991at Institut Paoli Calmettes, this program being one of the most active in Europe. He is Professor of Medicine at the Aix-Marseille University and scientific advisor of the hematology department, Ruijin Hospital, Shanghai, China.
Professor Blaise was a founding member of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), and a former president of this society. He has served on committees for numerous professional societies and advisory boards in the fields of Hematology and Stem Cell Transplantation. He is the author or co-author of more than 500 peer reviewed papers and the recipient of many national grants. His research interests focus on clinical transplantation, immunomodulation after allogeneic transplantation, immunotherapy of hematologic malignancies and solid tumors, and economic and social impact of allogeneic stem cell transplantation.
Info coming shortly.
Info coming shortly.
Physician at the Hematology Department in Saint Antoine Hospital, Paris, France. Teacher at Sorbonne University. Researcher at Inserm, UMRs 938. Faculty member of the EBMT, SFGM-TC, LYSA and IACH.
My main center of interests are bone marrow transplantation, lymphoma, CAR-T cells, management of drug-induced toxicities and immunology.
Florent Malard, MD, PhD, studied medicine at the University of Nantes, France and obtained his PhD degree at the University Pierre et Marie Curie in Paris, France, followed by a postdoctoral fellowship at the Memorial Sloan Kettering Cancer Center, New York, USA. He is now appointed as an Associate Professor at Saint-Antoine Hospital, Paris, France. His research works focused on allogeneic stem-cell transplantation, immunology and multiple myeloma. He has published so far over 50 publications on these topics., MD, PhD, studied medicine at the University of Nantes, France and obtained his PhD degree at the University Pierre et Marie Curie in Paris, France, followed by a postdoctoral fellowship at the Memorial Sloan Kettering Cancer Center, New York, USA. He is now appointed as an Associate Professor at Saint-Antoine Hospital, Paris, France. His research works focused on allogeneic stem-cell transplantation, immunology and multiple myeloma. He has published so far over 50 publications on these topics.
Mohamad Mohty is full Professor of Hematology and head of the Hematology and cellular therapy Department at the Saint-Antoine Hospital and Sorbonne University (Paris, France).
Professor Mohty obtained his medical degree from the University of Montpellier, France, and his PhD from the University of Marseille, France. He also undertook post-doctoral work at the Hematology Department, Imperial College, Hammersmith Hospital, London, UK.
Professor Mohty’s is also head of a translational research team (INSERM team N°7) at the Saint-Antoine Research centre in Paris and his research is focused on the pathophysiology and immunobiology of normal and pathological antigen-presenting cells, especially the
impact of novel immunomodulatory agents such as proteasome inhibitors, IMiDs and
Professor Arnon Nagler, MD, MSc
Chaim Sheba Medical Center, Israel
• Director of the Division of Hematology, Chaim Sheba Medical Center, Israel
• Director of Bone Marrow transplantation and Cord Blood Bank, Chaim Sheba Medical Center, Israel
• Professor of Medicine at the Tel Aviv University, Tel Aviv, Israel
• One of the pioneers of the non-myeloablative and reduced intensity/toxicity allogeneic transplantations
for both malignant and non-malignant disorders (Blood 1998)
• Established the first public cord blood bank and performed the first cord blood transplanataion in Israel
• Leader of the Alternative donor subcommittee of the ALWP of the EBMT from 2008-2010
• Leader of the RIC subcommittee of the ALWP of the EBMT – since 2010
• Serves on the Editorial Board of several BMT and Hematology Journals and is a Section Editor for
• Vice Chair of the Acute Leukemia Working Party (ALWP) of the EBMT
Zinaida Peric is a hematologist at the University Hospital Centre Zagreb and a post doctoral research assistant at the School of Medicine, University of Zagreb, Croatia. Dr Peric’s research activity is focused on the immunobiology of antigen-presenting cells in graft-vs-host diseaseand the role of gut microbiota in the pathogenesis of intestinal GVHD.Her clinical interests focus on early infectious complications, long-term complications and quality of life after allogeneic stem cell transplantation. Dr Peric is the Secretary of the Transplant Complications Working Party of the of the European Group for Blood and Marrow Transplantation (EBMT).
Bipin N. Savani
Bipin N. Savani, M.D.
Professor of Medicine
Director, Long Term Transplant Clinic
Medical Director, Stem Cell Transplant Processing Laboratory
Vanderbilt University Medical Center & Veterans Affairs Medical Center Nashville, TN USA
Dr Savani’s area of specialization is in the treatment of hematological malignancies and stem cell transplantation, and his primary field of research is in the long-term follow-up after transplantation, including regimen-related toxicity/ supportive care, and outcomes analysis of transplant recipients. Dr Savani has published over 350 peer-reviewed articles, reviews, book chapters, editorials, perspectives and commentaries in the field of hematological malignancies and stem cell transplantation. He is an associate editor of the journals British Journal of Haematology, Bone Marrow Transplantation and Biology of Blood and Marrow Transplantation; and serves as an editorial advisory board member for several journals in the field.